Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro

Drugs commonly administered to patients infected with the human immunodeficiency virus (HIV) have been studied for their propensity to alter the intracellular phosphorylation of the anti-HIV nucleoside analog stavudine (2',3'-dideoxy-2',3'-didehydrothymidine; d4T) in peripheral blood mononuclear cells (PBMCs) and U937 cells in vitro. PBMCs isolated from the blood of healthy volunteers were stimulated by the mitogen phytohemagglutinin (10 microg/ml) for 72 h. Stimulated PBMCs (3 x 10(6) cells/plate) were then incubated with [3H]d4T (0.65 microCi; 3 microM) and either acyclovir, dapsone, ddC, ddI, fluconazole, foscarnet, ganciclovir, itraconazole, lobucavir, ranitidine, ribavirin, rifampin, sorivudine, sulfamethoxazole, trimethoprim, lamivudine (3TC), zidovudine, or thymidine (30 and 300 microM) for 24 h. Doxorubicin and drugs showing some evidence of inhibition were also studied at 0.3 and 3 microM. Cells were extracted overnight with 60% methanol prior to analysis by radiometric high-performance liquid chromatography. Additional data for nine of the drugs were obtained by incubation with [3H]d4T in U937 cells for 24 h. The effect of d4T (0.2 to 20 microM) on zidovudine (0.65 microCi; 0.018 microCi) phosphorylation was also studied. Zidovudine significantly reduced d4T total phosphates in PBMCs and U937 cells (in PBMCs to 33% [P < 0.001] and 17% [P < 0.001] of that in control cells at 3 and 30 microM, respectively). A small reduction in zidovudine phosphorylation was seen with d4T but only at d4T:zidovudine ratios of 100 and 1,000. Of the other compounds screened, only thymidine, ribavirin, and doxorubicin produced inhibition of d4T phosphorylation in both PBMCs and U937 cells. However, doxorubicin was cytotoxic at 3 microM. The decrease in d4T phosphorylation in the presence of ribavirin is consistent with previous findings with zidovudine. Although ddC significantly inhibited the phosphorylation of d4T in PBMCs, this was not seen in U937 cells, and it is probable that the findings in PBMCs are related to mitochondrial toxicity [based on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide cytotoxicity assay]. The only drugs screened which may interfere with d4T phosphorylation at clinically relevant concentrations were zidovudine, ribavirin, and doxorubicin.

[1]  A. Breckenridge,et al.  The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites , 1996, AIDS.

[2]  J. Darbyshire,et al.  Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals , 1996, The Lancet.

[3]  S. Khoo,et al.  Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation. , 1996, AIDS.

[4]  M. Hirsch,et al.  Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. , 1996, The Journal of infectious diseases.

[5]  D. Back,et al.  Zalcitabine (ddC) Phosphorylation and Drug Interactions , 1995 .

[6]  R. Tubiana,et al.  Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. , 1995, The Journal of infectious diseases.

[7]  A. Cross,et al.  Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089. , 1995, The Journal of infectious diseases.

[8]  D. Back,et al.  Drug interactions with zidovudine phosphorylation in vitro. , 1994, Antimicrobial agents and chemotherapy.

[9]  D. Back,et al.  Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells. , 1994, British journal of clinical pharmacology.

[10]  J. Beijnen,et al.  Pharmacokinetic interaction between rifampin and zidovudine , 1993, Antimicrobial Agents and Chemotherapy.

[11]  J. Sommadossi Nucleoside analogs: similarities and differences. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  B. Gazzard,et al.  Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients , 1992, Antimicrobial Agents and Chemotherapy.

[13]  J. Cameron,et al.  Cellular metabolism of (-) enantiomeric 2'-deoxy-3'-thiacytidine. , 1992, Biochemical pharmacology.

[14]  C. H. Chen,et al.  The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2',3'-dideoxycytidine. , 1992, The Journal of biological chemistry.

[15]  J. Sommadossi,et al.  Metabolism and DNA interaction of 2',3'-didehydro-2',3'-dideoxythymidine in human bone marrow cells. , 1991, Molecular pharmacology.

[16]  H. Ho,et al.  Cellular pharmacology of 2',3'-didehydro-2',3'-dideoxythymidine (D4T) in human peripheral blood mononuclear cells. , 1990, Biochemical pharmacology.

[17]  F. Harwood,et al.  Cytostatic effects of 2',3'-dideoxyribonucleosides on transformed human hemopoietic cell lines. , 1990, Molecular pharmacology.

[18]  J. Starrett,et al.  1-(2,3-Dideoxy-β-D-glycero-pent-2-enofuranosyl)thymine. A Highly Potent and Selective Anti-HIV Agent. , 1989 .

[19]  H. Ho,et al.  Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus , 1989, Antimicrobial Agents and Chemotherapy.

[20]  M. Hansen,et al.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. , 1989, Journal of immunological methods.

[21]  E. De Clercq,et al.  Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. , 1989, The Journal of biological chemistry.

[22]  J. Starrett,et al.  1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent. , 1989, Journal of medicinal chemistry.

[23]  S. Broder,et al.  Pharmacokinetics of 2‘,3’‐Dideoxycytidine in Patients with AIDS and Related Disorders , 1988, Journal of clinical pharmacology.

[24]  E. De Clercq,et al.  Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro , 1987, Antimicrobial Agents and Chemotherapy.

[25]  E. De Clercq,et al.  The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2',3'-didehydro-2',3'-dideoxyribonucleosides: a comparison with their parental 2',3'-dideoxyribonucleosides. , 1987, Molecular pharmacology.

[26]  J. Longstreth,et al.  Ribavirin disposition in high‐risk patients for acquired immunodeficiency syndrome , 1987, Clinical pharmacology and therapeutics.

[27]  R. Schooley,et al.  Ribavirin antagonizes the effect of azidothymidine on HIV replication , 1987, Science.

[28]  J. Sommadossi,et al.  Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro , 1987, Antimicrobial Agents and Chemotherapy.

[29]  J Desmyter,et al.  Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. , 1987, Biochemical and biophysical research communications.

[30]  S. Broder,et al.  Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity. , 1986, Biochemical pharmacology.

[31]  G. Aronoff,et al.  Fluoxetine kinetics and protein binding in normal and impaired renal function , 1984, Clinical pharmacology and therapeutics.

[32]  S. Eksborg,et al.  Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol. , 1979, Journal of chromatography.

[33]  C. Heusghem,et al.  Pharmacokinetic Studies of Co‐Trimoxazole in Man After Single and Repeated Doses , 1974, Journal of clinical pharmacology.

[34]  S. Steinberg,et al.  2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. , 1993, The Journal of infectious diseases.

[35]  S. Broder,et al.  Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. , 1987, Biochemical pharmacology.